MedTrace Logo

Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension

NCT00353652 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2019-02-06

Study results available
· View outcomes & findings →

Summary

Thiazide medications are often prescribed for individuals with high blood pressure, but research has shown that they may increase an individual's risk of developing diabetes. While it is unknown exactly how thiazide causes this response, it is likely that the nervous system is somehow involved. This study will evaluate the role of the nervous system in sugar metabolism, as well as determine the effect of thiazide and other medications on individuals with high blood pressure.

Conditions

Interventions

DRUG

Study#1: chlorthalidone (CTD), titrated dose

Participants in study #1 will receive 3 months of chlorthalidone (12.5-25 mg/d) at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg

DRUG

Study #1: spironolactone (SP), titrated dose

Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg.

DRUG

Study# 2 chlorthalidone (CTD), fixed dose

Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.

DRUG

Study# 2 spironolactone (SP), fixed dose

Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.

DRUG

Study# 2 irbsesartan (IR), fixed dose

Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Wanpen Vongpatanasin, MD · University of Texas, Southwestern Medical Center at Dallas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00353652 on ClinicalTrials.gov